{
  "$schema": "folio-library-entry/v1",
  "id": "10665-42458",
  "blocks": [
    {
      "id": "library/10665-42458/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 5,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "GUIDELINES\nWHO/HIV_AIDS/2001.01\nWHO/RHR/01.10\nOriginal: English\nDistr.: General\nFOR THE MANAGEMENT OF\nSEXUALLY TRANSMITTED INFECTIONS\nWORLD HEALTH ORGANIZATION\nWHO/HIV_AIDS/2001.01\nWHO/RHR/01.10\nOriginal: English\nDistr.: General\nWORLD HEALTH ORGANIZATION\nL\nO\nN\nD\nO\nN\nS\nC\nH\nO\nO\nL\nO\nF\nH\nY\nG\nI\nE\nN\nE\n&\nT\nR\nO\nP\nI\nC\nA\nL\nM\nE\nD\nI\nC\nI\nN\nE\nFOR THE M N GEMENT OF\nSEXUALLY TRANSMITTED INFECTIONS\nFOR THE MANAGEMENT OF\nHERPES SIMPLEX VIRUS TYPE 2\nWHO/HIV_AIDS/2001.05\nUNAIDS/01.89E\nOriginal: English\nDistr.: General\nPROGRAMMATIC AND RESEARCH PRIORITIES\nIN DEVELOPING COUNTRIES\nW O R L D H E A LT H O R G A N I Z",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Front matter of the 2001 WHO/UNAIDS/LSHTM workshop report on herpes simplex virus type 2 (HSV2) programmatic and research priorities in developing countries, with title pages, document numbers, ISBN and copyright notice, followed by a list of abbreviations. The extracted text also includes stray cover text from an unrelated WHO publication, Guidelines for the management of sexually transmitted infections.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ABBREVIATIONS",
      "pageStart": 5,
      "pageEnd": 6,
      "target": "../sections/sec-000-abbreviations.md",
      "narrative": null,
      "content": "iv\nHERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES\nABBREVIATIONS",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A running header followed by the heading for the list of abbreviations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EXECUTIVE SUMMARY",
      "pageStart": 6,
      "pageEnd": 8,
      "target": "../sections/sec-001-executive-summary.md",
      "narrative": null,
      "content": "Herpes simplex virus type 2 (HSV2) infection is the primary cause of genital herpes. It is\nhighly prevalent in human populations in many parts of the world, and is the most\ncommon cause of genital ulcer disease worldwide.\nIn developing countries, the major public health importance of HSV2 relates to its\npotential role in facilitating HIV transmission. HSV2 is highly prevalent in most regions\nexperiencing severe HIV epidemics, with infection rates rising steeply with age to reach\nlevels of 70% or more among adult women and men in some African countries. Genital\nulcer disease enhances the infect",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the report, explaining that HSV2 is the main cause of genital ulcer disease, is very common where HIV epidemics are severe, and may facilitate HIV transmission in a two-way interaction. It notes that the workshop reviewed evidence and set priorities across epidemiology, HSV2–HIV interaction, therapy, vaccines and behavioural and microbicide studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "INTRODUCTION",
      "pageStart": 8,
      "pageEnd": 9,
      "target": "../sections/sec-002-1-introduction.md",
      "narrative": null,
      "content": "Herpes simplex virus type 2 (HSV2) infection is the primary cause of genital herpes. It is\nhighly prevalent in human populations in many parts of the world, and is the most\ncommon cause of genital ulcer disease worldwide.\nIn developing countries, the major public health importance of HSV2 relates to its\npotential role in facilitating HIV transmission. HSV2 is highly prevalent in most regions\nexperiencing severe HIV epidemics, with infection rates rising steeply with age to reach\nlevels of 70% or more among adult women and men in some African countries. Genital\nulcer disease enhances the infect",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the workshop by setting out the public health importance of HSV2 in developing countries and its suspected role in HIV spread. It explains that experts from developing and industrialized countries were invited to consider control measures.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "OBJECTIVES",
      "pageStart": 9,
      "pageEnd": 10,
      "target": "../sections/sec-003-2-objectives.md",
      "narrative": null,
      "content": "1. To review existing knowledge in the following four areas, with a particular focus on\ndeveloping countries:\n■The epidemiology and natural history of HSV2\n■The interaction between HSV2 and HIV\n■HSV2 control measures\n■HSV2 diagnostics.\n2.To identify important gaps in knowledge in each of these areas requiring further study.\n3.To establish priorities for future research and control programmes.\n2. OBJECTIVES\n2\n2. OBJECTIVES\nHERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States the workshop's objectives: to review knowledge on HSV2 epidemiology, its interaction with HIV, control measures and diagnostics, to identify knowledge gaps, and to set research and programme priorities.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PARTICIPANTS AND METHODOLOGY",
      "pageStart": 10,
      "pageEnd": 17,
      "target": "../sections/sec-004-3-participants-and-methodology.md",
      "narrative": null,
      "content": "Forty participants attended the workshop (Annex 1), and areas of expertise included\nvirology, epidemiology, surveillance, behavioural science, clinical medicine,\nmathematical modelling and STI programme development and implementation in\ndeveloping countries. Participants came from Africa (10),Asia (1), Europe (18) and\nNorth America (7). In addition, three representatives of UN agencies were present, and\none from GlaxoSmithKline.\nThe workshop was organised around the four topic areas listed above, with a session\ndevoted to each topic.The workshop included presentations by invited speakers, brea",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the 40 participants and the workshop's format of presentations, breakout groups and plenary prioritisation. It then reviews the epidemiology and natural history of HSV2, including rising prevalence worldwide and its role as the leading cause of genital ulcer disease. Table 1 gives seroprevalence figures for general populations in Africa, Latin America and Asia, and the section discusses HSV2 as a marker of sexual behaviour. It ends with recommended studies, including of discordant couples, with attention to counselling and treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1: HSV2 seroprevalence in general populations in developing countries",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table lists studies of HSV2 seroprevalence in general populations in developing countries, giving for each the country, population group, year, prevalence (by sex where reported) and reference. Rows are ordered by decreasing prevalence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Biological and clinical research",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/sec-005-51-biological-and-clinical-research.md",
      "narrative": null,
      "content": "HIV and HSV2 manifest a bi-directional interaction. HSV2 increases the efficiency of HIV\nacquisition and transmission whereas HIV may increase susceptibility to HSV2 and\nincrease HSV2 shedding, HSV2 recurrence rate and severity of clinical manifestations.\nEFFECT OF HIV INFECTION ON NATURAL HISTORY OF HSV2\nHSV2 reactivation and duration of recurrences are significantly increased in HIV infected\nindividuals [Augenbraun et al., 1995; Fennema et al., 1995].The frequency and severity of\nrecurrences increases as CD4 cell count decreases [Augenbraun et al., 1995; Fennema et\nal., 1995; Pannuti et al.,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the two-way biological interaction between HIV and HSV2, with HIV increasing HSV2 reactivation, shedding and severity, and HSV2 lesions containing HIV. It notes some evidence that aciclovir may prolong survival in people with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "INTERACTION BETWEEN HSV2 AND HIV",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-006-5-interaction-between-hsv2-and-hiv.md",
      "narrative": null,
      "content": "10\n5. INTERACTION BETWEEN HSV2 AND HIV\nHERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES\nassociation between genital HIV RNA and HSV2 DNA levels, but some association of\nquantity of HIV and HSV2 shedding among dually shedding women [Mbopi-Keou et al.,\n2000]. HIV RNA is often present at high titres in genital lesions (independent of plasma\nRNA levels), but titres of both HIV1 and HSV2 fall rapidly on treatment with aciclovir,\nsupporting the hypothesis that HSV2 reactivation may play an important role in \nup-regulation of HIV1 on mucosal surfaces.\nFew data",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the review of how HSV2 may increase HIV shedding, noting that aciclovir lowers both viruses in lesions and that data from developing countries are lacking. It lists recommended biological studies, such as whether the effect differs in Africa because of co-infections.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Epidemiological research",
      "pageStart": 18,
      "pageEnd": 20,
      "target": "../sections/sec-007-52-epidemiological-research.md",
      "narrative": null,
      "content": "EFFECT OF HSV2 ON HIV ACQUISITION\nEvidence for the effect of HSV2 on acquisition of HIV comes from epidemiological\nstudies, and results of a meta-analysis of the relationships between the two infections\nwere presented [Wald and Link, unpublished]. Nine prospective studies (four cohort\n5. INTERACTION BETWEEN HSV2 AND HIV\n11\nHERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES\nstudies and five nested case-control studies) were identified. Studies in men showed a\nconsistent two-fold increase in the risk of HIV acquisition. In contrast, the study in\nwomen did n",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises epidemiological evidence that HSV2 raises the risk of acquiring HIV, from a meta-analysis showing about a two-fold risk in men and weaker findings in women. It discusses why cross-sectional studies show stronger associations and recommends prospective studies and estimates of population attributable fractions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Genital ulcer disease in Africa: Epidemiological trends",
      "pageStart": 20,
      "pageEnd": 22,
      "target": "../sections/sec-008-53-genital-ulcer-disease-in-africa-epidemiologic.md",
      "narrative": null,
      "content": "Chancroid, syphilis and genital herpes are all common causes of genital ulcer disease\n(GUD) in developing countries. However, there is some evidence that there have been\nchanges in the aetiology of GUD in recent years [O’Farrell, 1999], and this may\ninfluence the appropriateness of current syndromic management.\nTable 2 shows data from a gold mine STI clinic in South Africa from 1986 to 1998 [Htun\net al., 2001].The proportions of GUD due to chancroid and syphilis decreased during the\nstudy period. Of the 239 GUD diagnosed in 1986, 53% were chancroid and 12%\nsyphilis. By 1998, 33% and 3% of 200",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes changes in the causes of genital ulcer disease in Africa, with Table 2 showing herpes rising and chancroid and syphilis falling at a South African mine clinic from 1986 to 1998. It notes that this undermines syndromic management and recommends monitoring ulcer causes by sex, HIV status and risk group.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Aetiology of GUD in a gold mine STI clinic, South Africa 1986-98",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "The table shows the aetiology of genital ulcer disease (GUD) among patients at a gold mine STI clinic in South Africa in 1986, 1990, 1994 and 1998, as numbers with percentage distribution. Rows give single aetiologies (chancroid, LGV, genital herpes, RPR positive), mixed infections, their totals and indeterminate cases.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HSV2 CONTROL MEASURES FOR DEVELOPING COUNTRIES",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-009-6-hsv2-control-measures-for-developing-countries.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case management of HSV2 in areas of Africa with high HIV prevalence",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-010-61-case-management-of-hsv2-in-areas-of-africa-wi.md",
      "narrative": null,
      "content": "IN AREAS OF AFRICA WITH HIGH HIV PREVALENCE\nClinical diagnosis of GUD is unreliable, reflecting similarities between the clinical\npresentation of different GUDs, the presence of mixed infections and atypical ulceration\ndue to longstanding disease (associated with delay in seeking health care).As mentioned\nin Section 5, HIV may alter the clinical presentation of HSV2. In areas of high HIV\nprevalence, herpetic ulcers are often necrotic and complicated with secondary bacterial\ninfections.This atypical presentation, added to the high prevalence of co-infections,\nmakes clinical diagnosis even more",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why clinical diagnosis of genital ulcers is unreliable where HIV is common and why rising herpes cases may increase syndromic treatment failure. It recommends lobbying for affordable aciclovir, evaluating its addition to syndromic algorithms, and strengthening health education.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The role of episodic and suppressive therapy in HSV2 and HIV control",
      "pageStart": 23,
      "pageEnd": 26,
      "target": "../sections/sec-011-62-the-role-of-episodic-and-suppressive-therapy.md",
      "narrative": null,
      "content": "IN HSV2 AND HIV CONTROL\nTwo main treatment strategies are possible for herpes: episodic and suppressive treatment.\n■Episodic therapy:\n➔Treatment of primary genital herpes\n➔Treatment of recurrent genital herpes\n■Suppressive therapy:\n➔To prevent recurrences.\nAciclovir is an antiviral drug, which has been the standard treatment for genital herpes\nfor the past decade in developed countries.Two new therapeutic agents (valaciclovir and\nfamciclovir) have recently become available, and are also effective and safe treatments\n[Wald, 1999]. However, they are also more expensive than aciclovir.\n6. HSV2 CO",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Compares episodic and suppressive therapy for genital herpes with aciclovir, valaciclovir and famciclovir, summarising their effects on symptoms, shedding and recurrences. It considers how such therapy might reduce HIV transmission or acquisition. It recommends randomised trials in high-risk groups, such as serodiscordant couples and sex workers, with monitoring for drug resistance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vaccine trials",
      "pageStart": 26,
      "pageEnd": 30,
      "target": "../sections/sec-012-63-vaccine-trials.md",
      "narrative": null,
      "content": "Given the high prevalence of HSV2 infection in many countries, and the fact that most\ninfections are subclinical, the development of an effective HSV2 vaccine would provide a\npowerful control tool.\nHSV2 vaccines can be divided into two main categories according to whether they target\ninfected or uninfected individuals.\nProphylactic vaccines: aim at protecting against HSV infection or disease in the uninfected\nindividual. Prophylactic vaccines have been shown to work in animal experiments.\n6. HSV2 CONTROL MEASURES FOR DEVELOPING COUNTRIES\n19\nHERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARC",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses prophylactic and therapeutic HSV2 vaccines, the immune responses they should induce and the results of recent candidate vaccine trials. It considers how vaccine trials could be designed in developing countries, with HSV2 disease as the main endpoint and HIV infection as a secondary one.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Other preventive strategies",
      "pageStart": 30,
      "pageEnd": 33,
      "target": "../sections/sec-013-64-other-preventive-strategies.md",
      "narrative": null,
      "content": "In the absence of a vaccine or feasible therapeutic strategy in many developing countries,\nother preventive strategies are needed for HSV2 (and HIV) control. Discussions focused\non female-controlled methods and behavioural interventions.\nREDUCING EXPOSURE TO THE VIRUS\nAs with other sexually transmitted infections, behavioural interventions are needed.The\nformat of these interventions will depend on current HSV2 epidemiology. In countries\nwith high HSV2 prevalence in the general population, such interventions will need to\ntarget the general population. In other countries with lower prevalence o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews other HSV2 prevention strategies where vaccines and therapy are not feasible, including behavioural interventions, condoms and female-controlled methods such as microbicides. It also covers counselling and states that widespread HSV2 screening was not recommended at that stage.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "MATHEMATICAL MODELLING",
      "pageStart": 33,
      "pageEnd": 34,
      "target": "../sections/sec-014-7-mathematical-modelling.md",
      "narrative": null,
      "content": "interactions between HSV2 and HIV.The modelling allows improved understanding of\nthe mechanisms of STI spread by analysing, interpreting and identifying gaps in\nempirical data and guiding future field studies. However, as the validity of the output\ndepends on the validity of the input, modelling does not usually provide quantitative\ncertainty.\nModelling HSV2 spread has highlighted that sexual behaviour patterns, such as age\nmixing, and biomedical factors, such as the duration of the period with recurrences, are\nmore important determinants of HSV2 incidence and prevalence than the frequency and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how mathematical modelling has been used to understand HSV2 spread and its interaction with HIV, and summarises findings on antiviral treatment and behaviour change. It lists further modelling needs, such as drug resistance, cost-effectiveness and vaccine effects.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HSV2 DIAGNOSIS",
      "pageStart": 34,
      "pageEnd": 36,
      "target": "../sections/sec-015-8-hsv2-diagnosis.md",
      "narrative": null,
      "content": "Evaluation of HSV2 assays is based on sensitivity, specificity and reproducibility, and\nindependent blinded comparison.\nSEROLOGY AND DIRECT TECHNIQUES TO DETECT HSV2 INFECTION\nThe gold standards for HSV2 serology include Western blot and immunoblot enzyme\nassays.These assays are based on detecting type-specific epitopes present within\nglycoproteins G and C (gG and gC).Western Blot is time consuming, expensive and\ntechnically difficult to replicate on a large scale, whereas ELISA tests are more widely\navailable and have been developed into commercial assays [Cowan, 2000].\nSeveral approaches all",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews HSV2 diagnostic methods, including gold-standard Western blot, commercial ELISA tests, ways to measure incidence, and PCR detection of viral shedding. It lists research needs, such as evaluating assays on African sera and developing rapid tests for herpetic ulcers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "RESEARCH AND CONTROL PROGRAMME PRIORITIES",
      "pageStart": 36,
      "pageEnd": 37,
      "target": "../sections/sec-016-9-research-and-control-programme-priorities.md",
      "narrative": null,
      "content": "Agreed priorities for control programmes and future research are summarized below.\n9.1. EPIDEMIOLOGICAL STUDIES AND NATURAL HISTORY OF HSV2\n■Analysis of sera from past and present studies to obtain HSV2 prevalence data\nLimited data on HSV2 prevalence are available at present. It was recommended that stored\nsera from past and current studies be tested in order to increase data on HSV2 prevalence\nand incidence in different populations.Testing will also allow analysis of past prevalences\nand trends to gain insight into the relative timing of HSV2 and HIV epidemics.\n■Use of sentinel surveillance s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the agreed research and control priorities, starting with epidemiology and natural history, such as testing stored and sentinel surveillance sera for HSV2 prevalence and using cohort data to study the effect of HSV2 on HIV acquisition by sex and age.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Biological studies: HSV2 and its interaction with HIV",
      "pageStart": 37,
      "pageEnd": 37,
      "target": "../sections/sec-017-92-biological-studies-hsv2-and-its-interaction-w.md",
      "narrative": null,
      "content": "■Clinical studies to assess the effect of subclinical HSV2 infection on HIV shedding\nThere is strong evidence of the bi-directional interaction between HIV and HSV2 in co-\ninfected subjects. However, there is insufficient evidence concerning the effect of\nasymptomatic HSV2 shedding on HIV transmission. Studies of HIV shedding in HSV2-\ninfected subjects, and of the relative importance of unrecognized HSV2 infection and\nsubclinical shedding for HIV transmission, are urgently needed. HIV shedding should be\nexamined according to HSV2 shedding, HSV2 symptom status, stage of HIV infection\nand sex.\nS",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the priority for clinical studies of how subclinical HSV2 shedding affects HIV shedding and transmission, ideally in areas with high rates of both infections.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Episodic and suppressive therapy",
      "pageStart": 37,
      "pageEnd": 39,
      "target": "../sections/sec-018-93-episodic-and-suppressive-therapy.md",
      "narrative": null,
      "content": "■Monitoring GUD aetiology in STI clinic attenders by gender and HIV status\nChanges in the aetiology of GUD in some countries has been associated with an increase\nin the frequency of treatment failure when using the syndromic approach to diagnose\nand treat STIs. High priority should be given to studies of GUD aetiology, especially in\nareas in which the proportion of ulcers of unknown aetiology is large and where HIV\nprevalence is high.These studies could be nested within studies of the impact of episodic\ntreatment on HIV shedding and should be carried out in different groups of the\npopulation (",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists treatment-related priorities, including monitoring the causes of genital ulcers in clinic attenders by sex and HIV status, assessing aciclovir in syndromic management, and studying the effect of episodic therapy on HIV shedding. It also calls for randomised trials of suppressive therapy to prevent HIV in high-risk groups.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vaccination",
      "pageStart": 39,
      "pageEnd": 40,
      "target": "../sections/sec-019-94-vaccination.md",
      "narrative": null,
      "content": "It was agreed to form a working group to establish a dialogue with commercial\ncompanies involved in HSV2 vaccine development and production.The group should\nengage these companies in discussions regarding further development and testing of the\ntwo types of HSV2 vaccine, prophylactic and therapeutic. Specifically, the group would:\n■Lobby for further investment in prophylactic vaccine development, including\ndevelopment and testing of the DISC vaccine for prophylactic use\n■Lobby to ensure availability and affordability of vaccine products in developing countries\n■Work towards creating partnership",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Proposes a working group to engage vaccine companies, lobby for prophylactic vaccine development and affordability in developing countries, and advance the DISC vaccine to later-phase trials.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Behavioural and microbicide studies",
      "pageStart": 40,
      "pageEnd": 40,
      "target": "../sections/sec-020-95-behavioural-and-microbicide-studies.md",
      "narrative": null,
      "content": "■Re-emphasis on primary prevention: behaviour modification and condom use\nContinued emphasis must be placed on reducing exposure to HSV2 and HIV through\nbehavioural modiﬁcation and condom use.These messages are particularly important for\nyoung people, who are at very high risk of HSV2 infection in many developing countries.\n■Evaluate counselling strategies for HSV2 in seropositive individuals\nEvaluation of HSV2 counselling strategies is urgently needed, focusing on newly-\nacquired HSV2 infections, particularly among young people.There is a need to define\neffective strategies using community-ba",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists behavioural and microbicide priorities, including continued promotion of behaviour change and condoms, evaluation of HSV2 counselling and clinic management of herpes, and including HSV2 as an outcome in microbicide trials.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Mathematical modelling",
      "pageStart": 40,
      "pageEnd": 41,
      "target": "../sections/sec-021-96-mathematical-modelling.md",
      "narrative": null,
      "content": "Work should continue on mathematical modelling allowing prediction of the impact of\nalternative control approaches on the HIV and HSV2 epidemics in a given population.\n■Continue modelling the transmission and control of HSV2, and its interaction with HIV\n■Model the risk of development of drug resistance\n■Model cost-effectiveness of alternative treatment strategies\n■Model the effects of vaccination, including indirect effects on HIV incidence.\n9. RESEARCH AND CONTROL PROGRAMME PRIORITIES\n33\nHERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends further modelling of HSV2 transmission and control, drug resistance, the cost-effectiveness of treatment strategies and the effects of vaccination on HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnosis",
      "pageStart": 41,
      "pageEnd": 42,
      "target": "../sections/sec-022-97-diagnosis.md",
      "narrative": null,
      "content": "■Rapid diagnostic tests for herpes ulcers\nEvaluation of algorithms for syndromic management of GUD is needed, with possible\nuse of aciclovir for severe ulcers.To avoid over-treatment, development of rapid\ndiagnostic assays for GUD should be a high priority.\n■Evaluation of current serological tests on panels of African sera\nStudies of the performance of current serological assays are needed to investigate\ndiscrepant results in sera from African sites. Coordination and exchange of information\nbetween different laboratories using these tests in developing countries should be\nstrengthened.\n9. RESE",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists diagnostic priorities: rapid tests for herpes ulcers to guide syndromic management, and evaluation of serological tests on African sera.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "LIST OF PARTICIPANTS",
      "pageStart": 42,
      "pageEnd": 45,
      "target": "../sections/sec-023-annex-1-list-of-participants.md",
      "narrative": null,
      "content": "Michel Alary\nDepartment of Infectious and \nTropical Diseases\nLondon School of Hygiene \nand Tropical Medicine\nKeppel Street\nLondon WC1E 7HT\nUnited Kingdom\nTel: +44 20 7612 7972\nFax: +44 20 7637 4314\nEmail: michel.alary@lshtm.ac.uk\nSevgi Aral\nDivision of STD\nPrevention/CDC\n1600 Clifton Road Mail-stop E02\nAtlanta, GA 30333\nUSA\nTel: +1 404 639 8259\nFax: +1 404639 8608\nEmail: soa1@cdc.gov\nMamadou Ball\nWorld Health Organization\n88 Enterprise Road\nHighlands\nHarare\nZimbabwe\nTel: +263 4746 835\nFax: +263 474 6867\nEmail: ballm@whoafr.org\nLaurent Belec\nHôpital Européen \nGeorges Pompidou\nUnité de Virologie",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1, the list of workshop participants with their institutions and contact details, running into the start of the reference list.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-42458/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "REFERENCES",
      "pageStart": 45,
      "pageEnd": 52,
      "target": "../sections/sec-024-annex-2-references.md",
      "narrative": null,
      "content": "38\nANNEX 2. REFERENCES\nHERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES\nCorey L, Mindel A, Fife KH, Sutherland S, Benedetti J,Adler MW. Risk of recurrence after\ntreatment of ﬁrst-episode genital herpes with intravenous aciclovir.\nSex Trans Dis 1985; 12 (4):215-218.\nCorey L, Langenberg AGM,Ashley R, Sekulovich RE, Izu AE, Douglas JM, Handsfield HH\net al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection.\nTwo randomized controlled trials. JAMA 1999; 331-340.\nCowan FM, Johnson AM,Ashley R, Corey L, Mindel A.Antibody to herpes s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the report, citing mainly studies on HSV2 epidemiology, treatment, vaccines and interaction with HIV, ending with WHO and UNAIDS contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
